Saturday 17 October 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.

231.83 2.20 −0.94%

Follow ALNY

Alert me

Market cap: $31.3B
P/E: 39.5×
Fwd P/E: 39.6×
Dividend yield: —
F-score: 6/9
Altman Z: 7.30
Beneish M: −1.95
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 43.95

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	5	6	10	1	—	1	—	—	—	1

Insider Ownership 0.17%

Capital & Financial Ratios $m

Market Cap 31,320.00

Revenue 4,804.18

Net Income 774.71

Free Cash Flow 819.87

Net Debt (2,297.17)

Current Ratio 3.05

Debt/Equity 0.75

P/E ratio 39.50

Fwd P/E 39.60

P/S ratio 6.45

P/B ratio 22.87

Past 5Y EPS Growth —

This Y EPS Growth 185.30%

Next Y EPS Growth 48.11%

Next Y revenue growth 47.50%

Next 5Y EPS Growth 73.13%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.92%

10-year low 10-year high

P/B against its own 10 years 63.61%

10-year low 10-year high

EV/Sales against its own 10 years 0.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2,439	2,695	2,908	3,308
Receivables	328	405	778	913
Inventory	89	79	83	97
Other	—	—	—	—
	2,983	3,295	4,051	4,620

	2023	2024	2025	Q'26
Payables	56	88	116	108
ST’ Debt	—	—	—	—
Other	55	207	220	259
	968	1,186	1,466	1,513

Compound Annual Growth %

	10y	5y	3y
Sales	56.89%	49.77%	52.98%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(4.61%)	(4.93%)	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,167	1,291	—	—	—
’25	594	774	1,249	1,097	3,714
’24	494	660	501	593	2,248
’23	319	319	751	440	1,828
’22	213	225	264	335	1,037
’21	178	221	188	259	844
’20	99	104	126	164	493

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	71	327	—	—	—
’25	(120)	130	351	164	524
’24	(82)	124	44	(95)	(8)
’23	(166)	(59)	359	(30)	104
’22	(171)	(123)	(115)	(132)	(541)
’21	(236)	(122)	(134)	(150)	(642)
’20	(246)	(135)	(110)	(123)	(615)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	49	292	—	—	—
’25	(129)	116	339	140	465
’24	(94)	116	40	(104)	(43)
’23	(180)	(75)	342	(45)	42
’22	(189)	(139)	(132)	(154)	(613)
’21	(253)	(133)	(160)	(172)	(718)
’20	(266)	(152)	(123)	(145)	(685)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.51	1.21	—	—	—
’25	(0.14)	(0.51)	1.84	1.20	2.33
’24	(0.52)	(0.13)	(0.87)	(0.65)	(2.18)
’23	(1.40)	(2.21)	1.15	(1.10)	(3.52)
’22	(2.00)	(2.29)	(3.32)	(1.68)	(9.30)
’21	(1.71)	(1.61)	(1.72)	(2.16)	(7.20)
’20	(1.62)	(1.56)	(2.18)	(2.09)	(7.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	31.38	35.98	60.27	65.81	84.97	124.00	117.58	148.10	141.98	205.87	Analyst estimates 2026–2028 Powerpack
	High	98.00	147.63	153.99	125.72	167.33	212.00	242.97	242.39	304.39	495.55
People
People	Employees	514	749	1,065	1,323	1,453	1,665	2,002	2,100	2,230	2,770
	Revenue/emp, $m	0.09	0.12	0.07	0.17	0.34	0.51	0.52	0.87	1.01	1.34
Income, $m
Income, $m	Revenue	47	90	75	220	493	844	1,037	1,828	2,248	3,714
	Gross margin, %	100.00	100.00	97.59	88.60	84.16	83.40	83.73	83.02	85.62	81.64
	EBT	(410)	(491)	(761)	(885)	(856)	(852)	(1,127)	(434)	(377)	323
	EBT margin, %	(869.63)	(545.95)	(1,015.48)	(402.85)	(173.60)	(100.93)	(108.63)	(23.71)	(16.79)	8.70
	Net income	(410)	(491)	(761)	(886)	(858)	(853)	(1,131)	(440)	(278)	314
	Depreciation	15	12	15	54	74	90	44	54	57	56
Per share, $
Per share, $	Revenue	0.55	0.99	0.74	2.01	4.29	7.13	8.53	14.64	17.61	28.35
	Earnings	(4.79)	(5.42)	(7.57)	(8.11)	(7.46)	(7.20)	(9.30)	(3.52)	(2.18)	2.39
	Cash flow	(3.59)	(4.23)	(5.59)	(2.55)	(5.35)	(5.42)	(4.45)	0.83	(0.07)	4.00
	Capex	(0.75)	(1.15)	(1.26)	(1.28)	(0.61)	(0.64)	(0.59)	(0.50)	(0.27)	(0.45)
	Free cash flow	(4.35)	(5.38)	(6.85)	(3.83)	(5.96)	(6.06)	(5.04)	0.34	(0.33)	3.55
	Book value	10.75	19.51	12.94	13.17	8.84	4.97	(1.30)	(1.77)	0.53	6.02
	Shares, m	86	91	101	109	115	118	122	125	128	131
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	163.12
	P/S	70.13	132.79	97.91	57.26	30.32	23.79	27.40	13.32	13.36	14.03
	P/B	3.59	6.76	5.63	8.75	14.71	34.15	0.00	0.00	447.73	66.01
	EV/Sales	60.02	114.32	83.83	51.53	26.91	21.71	26.27	12.54	12.62	13.51
	EV/FCF	(7.60)	(21.11)	(9.11)	(27.05)	(19.35)	(25.52)	(44.43)	546.65	(666.08)	107.85
Cash, $m
Cash, $m	Operating cash flow	(308)	(383)	(563)	(278)	(615)	(642)	(541)	104	(8)	524
	Capex	(65)	(104)	(127)	(140)	(70)	(76)	(72)	(62)	(34)	(59)
	Free cash flow	(372)	(487)	(690)	(419)	(685)	(718)	(613)	42	(43)	465
Balance, $m
Balance, $m	Working capital	540	1,620	1,021	1,363	2,030	2,113	1,924	2,015	2,109	2,584
	Total debt	150	30	30	276	191	676	1,017	1,021	1,025	1,008
	Net debt	(477)	(1,661)	(1,054)	(1,260)	(1,683)	(1,760)	(1,175)	(1,419)	(1,670)	(1,901)
	Shareholders’ equity	920	1,766	1,302	1,439	1,016	588	(158)	(221)	67	789
Returns, %
Returns, %	ROA	(30.96)	(30.14)	(42.67)	(44.64)	(29.58)	(24.19)	(31.47)	(11.94)	(6.89)	6.82
	ROIC	(59.85)	(295.38)	(205.47)	(328.88)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(37.54)	(36.54)	(49.63)	(64.66)	(69.92)	(106.31)	(526.14)	232.40	362.29	73.28

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RVMD Revolution Medicines, Inc.	$40.6B	— (loss-making)	— (loss-making)	−77.89% (below 0%: shrinking)	n/m	−69.98% (below 0%: shrinking)	100.00%	0.00%	Compare
ONC BeOne Medicines Ltd. - Sponsored ADR	$39.0B	62.6×	40.2×	+29.63% (above 0%: growing)	+143.68% (above 0%: growing)	+117.92% (above 0%: growing)	89.76%	19.06%	Compare
RPRX Royalty Pharma PLC	$34.3B	42.3×	21.9×	+16.50% (above 0%: growing)	−40.00% (below 0%: shrinking)	+31.57% (above 0%: growing)	100.00%	19.75%	Compare
ALNY Alnylam Pharmaceuticals, Inc.	$31.3B	39.5×	39.6×	+66.86% (above 0%: growing)	n/m	+152.82% (above 0%: growing)	76.88%	17.93%
ROIV Roivant Sciences Ltd.	$24.6B	— (loss-making)	— (loss-making)	−33.55% (below 0%: shrinking)	n/m	−29.99% (below 0%: shrinking)	80.31%	(25,380.93%)	Compare
INCY Incyte Corporation	$23.0B	13.9×	15.6×	+37.72% (above 0%: growing)	+39.71% (above 0%: growing)	+1,829.52% (above 0%: growing)	93.73%	41.69%	Compare
BNTX BioNTech SE Sponsored ADR	$22.7B	— (loss-making)	— (loss-making)	−58.53% (below 0%: shrinking)	n/m	−342.04% (below 0%: shrinking)	8.14%	(897.82%)	Compare
GMAB Genmab A/S Sponsored ADR	$22.6B	29.1×	21.0×	+24.86% (above 0%: growing)	−9.26% (below 0%: shrinking)	−7.69% (below 0%: shrinking)	92.73%	32.47%	Compare
INSM Insmed, Inc.	$21.7B	— (loss-making)	— (loss-making)	+296.11% (above 0%: growing)	n/m	+54.52% (above 0%: growing)	84.20%	(0.36%)	Compare
Median of peers	$23.8B	35.7×	21.5×	+20.68%	+15.23%	+11.94%	91.25%	9.53%

All 614 Biotechnology stocks →

Alnylam Pharmaceuticals, Inc. (ALNY) key facts

Strength: Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
Alnylam Pharmaceuticals, Inc. (ALNY) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALNY traded at $231.83, a market capitalization of $31.3 billion.
Return on equity was 73.3% and debt-to-equity 0.75.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 7.30 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.